- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Nycomed extends GPO deal to Novation
Nycomed Amersham Imaging of Princeton, NJ, has extended its contrast agent supply relationships with group purchasing organizations VHA and University HealthSystem Consortium (UHC) to Novation, the new company formed to supply the GPOs. The extension
Nycomed Amersham Imaging of Princeton, NJ, has extended its contrast agent supply relationships with group purchasing organizations VHA and University HealthSystem Consortium (UHC) to Novation, the new company formed to supply the GPOs. The extension also incorporates new Nycomed contrast agents not covered in the previous deals, such as the companys Teslascan MRI liver imaging agent.
Nycomed Amersham previously had separate contrast supply deals with VHA of Irving, TX, and UHC of Oak Brook, IL. Those GPOs in January spun off their supply and purchasing organizations to form Novation, so Nycomed Amersham began negotiating a supply deal with the new entity.
The new agreement covers contrast agent purchasing for the next five years, beginning in January. It also includes provisions that should increase compliance among VHA and UHC members, according to a Nycomed Amersham spokesperson.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI Have an Impact with Fertility-Sparing Treatments for Endometrial and Cervical Cancers?
January 9th 2025In a literature review that includes insights from recently issued guidelines from multiple European medical societies, researchers discuss the role of magnetic resonance imaging (MRI) in facilitating appropriate patient selection for fertility-sparing treatments to address early-stage endometrial and cervical cancer.
